Key Takeaways
- Moderna shares rallied up to 9.1% following FDA staff briefing documents that revealed no “major deficiencies” in the mFlusiva mRNA flu vaccine application
- The Vaccines and Related Biological Products Advisory Committee (VRBPAC) will convene June 18 to determine whether mFlusiva’s benefits justify its risks for individuals 50 and above
- Approval would mark mFlusiva as America’s first mRNA-based seasonal influenza vaccine, with the FDA’s final ruling anticipated by August 5
- The biotech firm is pursuing standard approval for the 50–64 age bracket and accelerated approval for those 65 and older
- Simultaneously, Moderna revealed a strategic leadership overhaul, appointing Ester Banque as Chief Commercial Officer in preparation for three anticipated product rollouts between 2027 and 2028
Moderna (MRNA) shares surged by as much as 9.1% Tuesday following the publication of FDA staff briefing documents indicating that data supporting the mFlusiva flu vaccine may demonstrate effectiveness in adults aged 65 and above. The stock reached approximately $56.12, approaching its 52-week peak of $57.80.
The briefing materials emerged prior to Thursday’s scheduled Vaccines and Related Biological Products Advisory Committee (VRBPAC) session, where members will determine whether mFlusiva’s advantages outweigh potential risks for Americans 50 years and older.
Most significantly, FDA staff identified no “major deficiencies” within the submission—precisely the signal Wall Street had anticipated.
The regulatory journey hasn’t been smooth. This past February, the FDA delivered a “refuse-to-file” notification, expressing reservations about trial methodology, particularly that the control group for individuals 65 and up received standard-dose flu vaccine instead of the high-dose formulation recommended by the CDC for that demographic. The agency quickly reversed its position after Moderna consented to modify its submission.
That regulatory turbulence unsettled markets. Tuesday’s briefing materials represented a decisive shift in regulatory sentiment.
Jefferies analyst Andrew Tsai characterized the evaluation as positive, forecasting $750 million in combined U.S. influenza and COVID-flu combination vaccine revenue by 2030.
FDA Staff Assessment Details
FDA evaluators observed that mFlusiva demonstrated superior relative vaccine efficacy compared to standard-dose flu vaccines in individuals aged 50 to 64. For the 65-plus demographic, the submission relies on immunogenicity evidence rather than direct efficacy measurements against high-dose comparators.
Reviewers highlighted certain constraints. The vaccine has undergone testing during only a single flu season, and immunocompromised individuals along with extremely frail elderly participants were excluded from trials, creating uncertainty about performance in those populations.
Moderna has committed to conducting supplementary research and providing additional data for the 65-and-above cohort should it secure accelerated approval for that population segment.
The biotechnology company seeks conventional approval for adults between 50 and 64 while pursuing accelerated approval for those 65 and older. The FDA’s ultimate determination is anticipated by August 5.
Approval would establish mFlusiva as the United States’ inaugural mRNA-based seasonal influenza vaccine.
Leadership Transformation Precedes Product Pipeline Expansion
Coinciding with the FDA news, Moderna unveiled an organizational restructuring. The company designated Ester Banque as Chief Commercial Officer, a strategic appointment designed to position the enterprise for as many as three product introductions—including a combined flu/COVID vaccine and a norovirus vaccine—slated for 2027 and 2028.
The convergence of favorable regulatory developments and a defined commercialization strategy provided sufficient momentum to drive shares upward.
Moderna has gained 81.8% year-to-date. Nevertheless, investors who allocated $1,000 to MRNA five years ago would currently hold only $283.65.
The VRBPAC decision is scheduled for June 18.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
